The FDA and the university have audited Kang Zhang for breaches in bioethics and a failure to follow research protocols.

The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.

The agency is now evaluating the implications of the corrupted data behind Zolgensma and whether to “take action” against the pharmaceutical company.

Two coauthors of a new study discuss their findings about nearly 170 facilities in the southwestern US selling unproven therapies—and what should be done about them.

Its screen for selected variants of some disease-linked genes gives customers an incomplete picture of their risk—do they know?

The agency issued a safety warning after two patients contracted antibiotic-resistant infections and one of the patients died.

The decision may facilitate the agency cracking down more effectively on the unproven interventions these companies sell.

FDA researchers report that multiple active ingredients wind up in users’ bloodstream and recommend toxicology testing to investigate the clinical significance of the findings.

The fast-growing fish can now be raised and sold in the US, although it’s likely to be some time before the product hits the market.